SC
ALXN

Samlyn Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Samlyn Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-84,100
Closed -$10.2M – 151
2017
Q2 		$10.2M Buy
84,100
+34,800
+71% +$4.05M 0.25% 81
2017
Q1 		$5.98M Buy
49,300
+15,300
+45% +$1.97M 0.14% 113
2016
Q4 		$4.16M Buy
+34,000
New +$4.16M 0.09% 107
2014
Q3 		– Sell
-129,000
Closed -$20.2M – 102
2014
Q2 		$20.2M Buy
129,000
+2,400
+2% +$379K 0.46% 72
2014
Q1 		$19.3M Sell
126,600
-158,100
-56% -$25.1M 0.45% 73
2013
Q4 		$37.8M Buy
+284,700
New +$34.2M 0.95% 45

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Samlyn Capital's ALXN Position: Q3 2017 in Review

Samlyn Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 84,100 shares — an estimated $10.2M sold.

Samlyn Capital first reported a position in ALXN in Q4 2013 and held it in 6 quarters. The position peaked at $37.8M in Q4 2013. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Samlyn Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Samlyn Capital sold 84,100 Alexion Pharmaceuticals shares in Q3 2017, an estimated $10.2M.
  • Samlyn Capital first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Samlyn Capital's Alexion Pharmaceuticals position peaked at $37.8M in Q4 2013.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Samlyn Capital's 13F filing for Q3 2017, filed 14 Nov 2017.